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Persistent bone disease in adult type 1 Gaucher
disease despite increasing doses of enzyme
replacement therapy
In Gaucher disease type I (GD, OMIM #230800), defi-
cient activity of the enzyme glucocerebrosidase results in
hepatosplenomegaly, cytopenia and skeletal disease.1
Skeletal disease leads to chronic bone pain and/or severe
complications such as pathological fractures, avascular
necrosis and bone crises. Enzyme Replacement Therapy
(ERT, Cerezyme, Genzyme, MA, USA) reverses many
symptoms of the disease with doses ranging between 15
and 120 U/kg/4weeks. Recently, it has been shown that
high dose ERT results in a more robust response in
Gaucher associated markers, such as chitotriosidase and
the bone marrow burden score.2 Although symptomatic
bone disease is usually treated with a relatively high dose
(60-120 U/kg/4weeks), bone marrow involvement may
persist.2 Whether it is useful to continue high dose or
increase the dose in these cases is currently unknown.
We describe one illustrative case and compared GD
patients with and without persistent bone disease with
respect to disease markers and the effect of dose. 
A male patient was diagnosed with GD (genotype
N370S/ G202R) at the age of 19 because of persistent
splenomegaly during an EBV infection. His first bone cri-
sis occurred at the age of 22 followed by recurrent crises
in the femurs, lumbar spine and septic arthritis of his
right knee. Splenectomy was performed at age 25
because of gross splenomegaly. ERT was started in 1991
(40 U/kg/4weeks) and normalization of liver volume and
modest decrease in chitotriosidase was observed. No
new bone complications occurred, although bone pain
persisted. Therefore, the dose of ERT was increased step-
wise to 120 U/kg/4weeks. After 14 years of ERT, chi-
totriosidase was still high (8018 nmol/mL/hr) and bone
marrow fat fraction low. In 2007 he underwent hip
replacement. Pathology of the femoral head showed min-
imal hematopoietic tissue, large necrotic areas in the cen-
ter and extensive fields of Gaucher cells (Figure 1). 
The files of all adult patients at the Academic Medical
Centre receiving ERT for >5 years (N=40), were
reviewed. Data on age, sex, splenectomy, severity score
index (SSI)3, weight, hemoglobin, platelet count, liver and
spleen volume, QCSI, chitotriosidase, dose and bone
complications were collected. Bone response was defined
as follows: adequate skeletal response (Group 1): absence
of bone complications and chronic bone pain during ERT;
treatment failure (Group 2): occurrence of bone complica-
tions (avascular necrosis, bone crisis or pathological frac-
tures) or chronic bone pain (requiring analgesics and
attributable to GD in the opinion of the physician) during
ERT. Chitotriosidase activity was measured as previously
described.4 Liver and spleen volumes were measured by
spiral computed axial tomography. To correct for changes
in bodyweight, liver ratio was calculated (liver
volume/bodyweight (mL/kg)). Bone marrow involve-
ment was assessed using Dixon QCSI of the lumbar
spine.5 Baseline and follow-up QCSI data were available
in 15 and 13 patients from group 1 and in one and 6
patients from group 2, respectively. Differences in base-
line characteristics were analyzed by the Mann-Whitney
or by the χ2 test. In our experience, chitotriosidase
decreases rapidly, with >80% decrease after five years in
good responders (unpublished results). Therefore, the
time to reach a 80% decrease in chitotriosidase levels and
the time to reach a QCSI of more than 23%6 were ana-
lyzed by life table analysis (Kaplan Meier). 
Differences were determined by the log rank test. At
baseline, patients from group 2 had lower bodyweight
and more severe disease, as evidenced by a higher SSI
and liver ratio, more splenectomies and more pre-ERT
bone complications (Table 1). 
In Group 1, dose was increased in 10/28 of patients
(36%), including all patients with pre-ERT bone compli-
cations, primarily because of suboptimal platelet or vis-
ceral response. In 3, chitotriosidase and/or fat fractions
showed an accelerated improvement after a dose increase
(median increase 22.5 U/kg/4 weeks [range 15-105]). In
group 2, 10/12 patients (83%, of which 9 patients had
pre-ERT bone complications), had a dose increase (medi-
an increase 45 U/kg/4 weeks [range 15-105]), two refus-
ing an increase. Chitotriosidase response improved in
only 2 patients and fat fraction remained unchanged.
After ten years, despite a dose increase to 120 U/kg/4
weeks in 4 patients, absolute QCSI was 14%, 6%, 21%
and 15%, compared to a median (range) of 48.5% (25-
65%) in group 1. The decrease in chitotriosidase was
48%, 57%, 80% and 52%, compared to a median (range)
of 85% (64-88%) in group 1. The time to reach a QCSI of
>23% was significantly slower in group 2 (median 132
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Figure 1. Cross section of left femur head (center). The microscop-
ic pictures above and below highlight (A) the yellowish areas con-
sisting of vital bone and marrow filled with confluent sheets of
Gaucher cells (100× magnification), (B) the conspicuous demarca-
tion zone with non-specific chronic inflammation with fibrosis
(50×), (C) a central area of necrotic cells surrounded by avital
bone devoid of osteocytes (100×), (D) small reddish islands of pre-
existent bone marrow with normal hematopoietic tissue (100×). 
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months) versus group 1 (median 24 months, p=0.001). At
five years of ERT, all patients from group 1 had reached
this goal, compared to 1 patient from group 2. The time
to >80% decrease in chitotriosidase was significantly
shorter (median 70 months in group 1 vs. 172 months in
group 2, p=0.008). 
We show that a subset of Gaucher type I patients expe-
rience ongoing bone disease despite increasing doses of
ERT. The selected case illustrates that sanctuary sites of
Gaucher cells can remain in the bone marrow. Possibly,
the remaining Gaucher cells escape the effects of ERT due
to altered vascularization and fibrosis, or sub-populations
of Gaucher cells differ in their ability to take up the
exogenous enzyme. Indeed, some Gaucher cells may
exhibit little immunoreactivity for the mannose receptor.7
Twelve out of 40 patients still experienced bone dis-
ease despite increasing doses of enzyme. We recently
described that these patients have generally higher MIP-
1β levels and lower bone marrow fat fractions.6,8
Assessment of baseline characteristics and response
parameters may provide a risk indication for failure of
skeletal response, being low body weight, longstanding
and severe pre-treatment disease manifestations, (previ-
ous bone complications, severe hepatomegaly and
splenectomy), as well as slow improvement in QCSI, chi-
totriosidase and MIP-1β8 during ERT. In these patients,
further dose increases are probably not effective, and
dose decrease to maintain adequate visceral control, as
well as alternative strategies including the addition of bis-
phosphonates or substrate reduction, could be explored. 
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Table 1. Baseline characteristics (at start of therapy) of patients
with (group 2) and without (group 1) severe bone disease after
start of ERT. 
Group 1 Group 2 p
N 28 12
age 48 (21-68) 51 (37-77) NS
Sex (male/female) 14/14 9/3 NS
Weight (kg) 74 (50-104) 66 (47-72) 0.026
Splenectomy 6 (21%) 8 (67%) 0.011
Severity Score Index 6 (3-18) 14 (7-19) <0.0001
Hemoglobin (mmol/L) 7.6 (6.4-9.0) 7.3 (6.5-9.1) NS
Platelet count (x109/L) 77 (41-240) 126 (16-473) NS
Chitotriosidase 35134 44973
(nmol/mL/hr) (12430-143758) (29703-151400) NS
MIP-1β (pg/mL) 199 (72-472) 250 (113-671) NS
Liver ratio (mL/kg) 37 (22-93) 63 (30-130) 0.014
Spleen volume (mL) 1131 (470-4526) 1400 (501-4821) NS
Patients with pre-ERT 7 (25%) 10 (83%) <0.0001
bone complications
Patients compound 4 (14%) 1 (8%) NS
heterozygous for N370S
Start dose 15 (15-60) 15 (15-50) NS
(U/kg/4 weeks)
Highest dose 30 (15-120) 60 (25-120) 0.007
(U/kg/4 weeks)
NS: not significant.
